Information Provided By: 
Fly News Breaks for January 4, 2019
FLXN
Jan 4, 2019 | 07:26 EDT
As previously reported, Benchmark analyst Bruce Jackson downgraded Flexion to Hold from Buy following last night's pre-announcement of Q4 results and issuance of lower than expected 2019 revenue guidance. While he continue to see Zilretta eventually becoming the standard of care for the treatment of osteoarthritis knee pain, Jackson recommends moving to the sidelines to "wait out the uncertainty" he sees in the near-term.
News For FLXN From the Last 2 Days
There are no results for your query FLXN
